The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. - Wikidata - wikimedia - TriplyDB

The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

http://www.wikidata.org/entity/Q54564143

about

Molecular Assays in Cytopathology for Thyroid Cancer Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma Progress in molecular-based management of differentiated thyroid cancer The BRAF(V600E) mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samples BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation The thyroid imaging reporting and data system on US, but not the BRAFV600E mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC.2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies.Impact of molecular testing in the diagnosis of thyroid fine needle aspiration cytology: data from mainland China.Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.Integrated data analysis reveals potential drivers and pathways disrupted by DNA methylation in papillary thyroid carcinomas.Predicting Extrathyroidal Extension in Patients With Papillary Thyroid Microcarcinoma According to a BRAF Mutation.Senescent tumor cells lead the collective invasion in thyroid cancer.BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis.The prognostic implication and potential role of BRAF mutation in the decision to perform elective neck dissection for thyroid cancer Molecular pathogenesis and mechanisms of thyroid cancer BRAF mutation may predict higher necessity of postoperative radioactive iodine ablation in papillary thyroid cancer Tumorigenesis of papillary thyroid cancer is not BRAF-dependent in patients with acromegaly.Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.HIF-1α polymorphism in the susceptibility of cervical spondylotic myelopathy and its outcome after anterior cervical corpectomy and fusion treatment.BRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patients Multikinase inhibitors use in differentiated thyroid carcinoma.Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.The Frequency and Clinical Implications of the BRAF(V600E) Mutation in Papillary Thyroid Cancer Patients in Korea Over the Past Two Decades.BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer Effect of BRAF mutational status on expression profiles in conventional papillary thyroid carcinomas Relationships of FOXE1 and ATM genetic polymorphisms with papillary thyroid carcinoma risk: a meta-analysis.BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.BRAF(V⁶⁰⁰E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis.BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma.Replication and Meta-Analysis of Common Gene Mutations in TTF1 and TTF2 with Papillary Thyroid Cancer.Comparison of the clinicopathological behavior of the follicular variant of papillary thyroid carcinoma and classical papillary thyroid carcinoma: A systematic review and meta-analysis Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.

P2860

1183ac39fa8bbbaef70fcfb6b28aaec595ff0f7c

P248

Q26823658-8694E855-5975-4DD7-BF1A-9E60A557E7B6 Q26853261-6F616D6D-B41A-4B9F-92EC-8D4178758287 Q26999887-93467C18-4B58-4601-9ED5-71EEEE5A2859 Q27852737-C3294D83-BB6B-41D9-A5FA-93EC25A79BCB Q27852780-C63C4AC3-8E39-4369-B57F-705B2019F59A Q27853042-89E6BA87-CADE-464E-AFF0-14163986FF13 Q28070226-FA8638D9-0E16-4EEF-8AC9-429C6CFB84AF Q28075975-9CF26915-2FE1-4598-962F-CA3179B6AC91 Q28548302-787E0E1F-9006-4DF7-9FC6-AF992BBD2167 Q30364216-F6E1EF8D-03D7-4612-8292-D765B58FC412 Q30367068-2A0053BC-18C2-4134-8F05-F4698E43B301 Q30458424-44B5374E-FBAE-440E-B63D-070BDCAC4F5A Q30769508-29692FFB-DAE2-405D-9B86-742B851E8DCB Q31114420-E9BF65C8-8730-4BA4-8974-77684CC29945 Q33629836-CC7B5B83-9895-492D-AB7A-B425360DD750 Q33662346-EEADAEC9-AF14-470A-9389-A5EFADA81994 Q33702243-D7374396-B3A3-4170-A0D6-EF3FBB835507 Q33826001-FA908309-32F5-47DC-AB38-7E404527A720 Q33973118-9FAD2A00-7A6D-47B7-97C3-405DB3D58FFF Q34329018-4981B80B-D8CC-4F6B-9374-77F5764665FB Q34335766-988B957B-7519-44D7-9DCF-DDF1F3FA4CEB Q34362091-10575B9A-876B-442E-ADD3-C980B9D53575 Q34388349-D74C938A-BEBD-4986-9E71-531269B4F378 Q34525641-27105A2E-9366-4E37-B2C4-86E8C64974A0 Q34637861-FB8439E8-00B9-4F69-80DD-E68F841FFFA0 Q34660901-510683D7-E9F4-4E0D-A3A1-773C3CBADE22 Q34716574-BC1A2B48-F488-4915-AAC5-261E6CDBBA38 Q34839781-C5E07E6F-405F-463E-A35B-03EFF38DFEB6 Q34919430-81EC5D3F-11C4-4AB5-B5B5-D77C987BB59D Q35042608-1A0EF3E1-4A03-4963-B8E4-BCA16DC3F36D Q35155420-10C286D1-FF09-4187-82F3-069C7089ED50 Q35543644-38553D47-95DE-448F-827C-8CD35D809F94 Q35692478-4CC62227-400E-4980-8048-8A42F45E0C12 Q35724853-5BDA248C-927A-4DE8-92ED-32E2EDFE2F44 Q35755353-634DCFAD-362C-49B3-96EF-315924B997D8 Q35769369-76C5D012-A758-4162-B2BF-CCFFFFF9B4F8 Q35803487-45E4B64D-F277-4E9F-A8F5-2F94AFF1A07C Q36339926-D5CE7DAD-9B13-4FC3-95CB-8FA7630CCE45 Q36468764-22BD9EFB-F777-4C03-9DAB-3918EA2EB976 Q36560914-53378ADD-6ECB-4DE4-9F0C-D4F9DAF986CA

P2860

The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

http://www.wikidata.org/entity/Q54564143

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

The association of the BRAF

@nl

The association of the BRAF(V6 ...... yroid cancer: a meta-analysis.

@en

type

label

The association of the BRAF

@nl

The association of the BRAF(V6 ...... yroid cancer: a meta-analysis.

@en

prefLabel

The association of the BRAF

@nl

The association of the BRAF(V6 ...... yroid cancer: a meta-analysis.

@en

P1433

Q54564143-F1CA1E7C-B542-47C0-98C0-4641D2BF2E43

P1476

Q54564143-58966AAB-7612-45BB-8516-B56C64BA81DE

P2093

Q54564143-12A82F5F-ED8A-4457-93F6-BAD4052AA410

Q54564143-1479DCDA-295F-4E1E-BCB7-C844CAD4DE8C

Q54564143-581975E8-6949-43F3-B5DD-33F072779649

Q54564143-62BE4468-E517-4DBB-8A0D-6E780E00DDF1

Q54564143-63AEF411-50EC-4238-B2AC-2FEA128238D6

Q54564143-87E733E2-ACAA-46CC-822D-6628D32D118E

Q54564143-9B8F549C-930E-4366-81E2-BE953B313F4F

Q54564143-DE42B83B-9BC4-44B4-AD86-11E83DACC930

Q54564143-FAAD8A88-2866-4EB3-B217-5964A7A3F8A9

P2860

Q54564143-038F6EE1-619D-4EE1-B12F-E17268EF2DB4

Q54564143-084BAF32-DFC6-4866-86C1-61139A4A3EBF

Q54564143-0E192664-C0DD-44D7-9D8E-6B0025BD3009

Q54564143-10630379-F91B-4BE4-98AD-63CFBF77D7F9

Q54564143-1D86B104-BA87-4613-A07B-B5ED39FBA40C

Q54564143-20842567-8F6E-4340-8F11-F8011F315C4F

Q54564143-2ABD958A-09A4-4312-A723-1EAC4447FCC0

Q54564143-306F4FC0-2D7D-48DC-A186-16EA5287080D

Q54564143-33942100-0E07-41FF-B06F-594516FA9DE0

Q54564143-41051E62-8244-43E9-A07D-9ADF5E7BAFE5

P304

Q54564143-95F25E87-A1F6-4448-A6F8-FA8B4D94919D

P31

Q54564143-72f0c5cd-5dbf-4f5d-9b3f-587081b2d77f

Q54564143-7EB02EC0-4ACB-4F6C-ABE2-F063F69E8D67

P356

Q54564143-D1297B74-15A2-4EB2-B560-8CDF41A81C8D

P407

Q54564143-75023B57-EF55-4CEB-BA5B-511C4FA9535E

P433

Q54564143-C6539E5B-E344-434F-9477-340FB5D4B7F4

P478

Q54564143-AA133952-0E47-4398-B1C7-076A9874E5F5

P50

Q54564143-548CD46E-7084-4659-9CCE-7E3A60303D22

Q54564143-670B3F3F-9501-4F40-98D4-E10BD94CDFB4

Q54564143-FC090757-2814-4754-B300-EBBF2410F15E

P577

Q54564143-4501D0F5-0A4A-450A-A1DC-73BD5BF45398

P5875

Q54564143-3CED76C9-C070-4C52-9BEA-8F6B55132728

P698

Q54564143-ABA35927-554C-411A-9DB5-9F964515FAC7

P921

Q54564143-4173F0D6-3625-4AED-A7B6-46DB206DBACF

P356

P1433

P1476

The association of the BRAF(V6 ...... yroid cancer: a meta-analysis.

@en

P2093

Bo Youn Cho

http://www.w3.org/2001/XMLSchema#string

Do Joon Park

http://www.w3.org/2001/XMLSchema#string

Hwa Young Ahn

http://www.w3.org/2001/XMLSchema#string

Jung Ah Lim

http://www.w3.org/2001/XMLSchema#string

Kwang Hyun Kim

http://www.w3.org/2001/XMLSchema#string

Kyung Won Kim

http://www.w3.org/2001/XMLSchema#string

Seo Kyung Hahn

http://www.w3.org/2001/XMLSchema#string

Yeo Kyu Youn

http://www.w3.org/2001/XMLSchema#string

You Jin Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Measuring inconsistency in meta-analyses

Mutations of the BRAF gene in human cancer

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.

BRAF(V600E) mutation and the biology of papillary thyroid cancer.

Prognostic utility of BRAF mutation in papillary thyroid cancer.

Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression

P304

1764-1773

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.26500

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51609945

http://www.w3.org/2001/XMLSchema#string

P698

21882184

http://www.w3.org/2001/XMLSchema#string

P921